title: The Future of Smallpox Vaccination: is MVA the key?
abstract: Eradication of the smallpox virus through extensive global vaccination efforts has resulted in one of the most important breakthroughs in medical history, saving countless lives from the severe morbidity and mortality that is associated with this disease. Although smallpox is now extinct in nature, laboratory stocks of this virus still remain and the subject of smallpox vaccination has gained renewed attention due to the potential risk that smallpox may be used as a biological weapon by terrorists or rogue states. Despite having the longest history of any modern vaccine, there is still much to be learned about smallpox vaccination and the correlates of protection remain to be formally defined. This Commentary will discuss the strengths and weaknesses of traditional smallpox vaccination in comparison with immunization using modified vaccinia virus Ankura (MVA), a non-replicating virus with a strong safety record but weakened immunogenicity.
authors.affiliation: Vaccine and Gene Therapy Institute, Oregon Health & Sciences University, 505 NW 185th Avenue, Beaverton, OR 97006, USA. slifkam@ohsu.edu.
authors.forename: Mark K
authors.initials: MK
authors.lastname: Slifka
references.citation: Nat Med. 2003 Sep;9(9):1131-7
references.pmid: 12925846
references.citation: J Immunol. 2003 Nov 15;171(10):4969-73
references.pmid: 14607890
references.citation: Lancet. 2005 Jan 29-Feb 4;365(9457):398-409
references.pmid: 15680454
references.citation: JAMA. 1970 Apr 20;212(3):441-4
references.pmid: 4392370
references.citation: N Engl J Med. 1969 Nov 27;281(22):1201-8
references.pmid: 4186802
references.citation: J Virol. 2002 Apr;76(7):3329-37
references.pmid: 11884558
references.citation: Nat Med. 2003 Sep;9(9):1125-30
references.pmid: 12925845
references.citation: Vaccine. 2000 Oct 15;19(4-5):483-91
references.pmid: 11027812
references.citation: J Exp Med. 2003 Apr 7;197(7):927-32
references.pmid: 12668642
references.citation: Munch Med Wochenschr. 1971 Aug 27;113(35):1149-53
references.pmid: 5109577
references.citation: N Engl J Med. 2002 Apr 25;346(17):1275-80
references.pmid: 11923489
references.citation: Bull World Health Organ. 1973 May;48(5):523-7
references.pmid: 4359679
references.citation: J Immunol. 2004 May 15;172(10):6265-71
references.pmid: 15128815
references.citation: Am J Epidemiol. 2004 Oct 1;160(7):642-51
references.pmid: 15383408
references.citation: Curr Opin Biotechnol. 2004 Dec;15(6):506-12
references.pmid: 15560976
references.citation: J Infect Dis. 1997 Apr;175(4):756-63
references.pmid: 9086127
references.citation: Nature. 2004 Mar 11;428(6979):182-5
references.pmid: 15014500
references.citation: J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
references.pmid: 9472619
references.citation: J Virol. 2001 Feb;75(3):1205-10
references.pmid: 11152493
references.citation: Dermatol Clin. 2004 Jul;22(3):263-74, vi
references.pmid: 15207308
references.citation: Am J Trop Med Hyg. 1972 Mar;21(2):214-8
references.pmid: 5061278
references.citation: N Engl J Med. 1967 Jan 19;276(3):125-32
references.pmid: 4381041
references.citation: Emerg Infect Dis. 2001 May-Jun;7(3):434-8
references.pmid: 11384521
references.citation: J Infect Dis. 2002 Jun 1;185(11):1657-9
references.pmid: 12023773
references.citation: Dtsch Med Wochenschr. 1974 Nov 22;99(47):2386-92
references.pmid: 4426258
references.citation: Vaccine. 1995 Apr;13(5):487-93
references.pmid: 7639016
references.citation: N Engl J Med. 2003 Jan 30;348(5):460-3
references.pmid: 12496354
references.citation: Curr Drug Targets Infect Disord. 2003 Sep;3(3):263-71
references.pmid: 14529359
references.citation: Bull World Health Organ. 1975;52(3):307-11
references.pmid: 1084801
references.citation: J Virol. 2004 Apr;78(8):3811-6
references.pmid: 15047796
references.citation: Br J Dermatol. 1994 Nov;131(5):598-607
references.pmid: 7999588
references.citation: Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5
references.pmid: 15070762
references.citation: Trends Microbiol. 1996 Oct;4(10):394-400
references.pmid: 8899965
references.citation: Emerg Infect Dis. 2003 Nov;9(11):1468-70
references.pmid: 14718095
references.citation: Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):217-22
references.pmid: 12518065
references.citation: Nat Rev Immunol. 2002 Jul;2(7):521-7
references.pmid: 12094226
references.citation: Rev Med Virol. 2002 Jul-Aug;12(4):201-9
references.pmid: 12125012
references.citation: Am J Epidemiol. 1971 Sep;94(3):252-68
references.pmid: 4999240
references.citation: N Engl J Med. 2004 Jan 22;350(4):342-50
references.pmid: 14736926
references.citation: JAMA. 2003 Jun 25;289(24):3295-9
references.pmid: 12824212
references.citation: Emerg Infect Dis. 2003 Nov;9(11):1458-61
references.pmid: 14718092
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63
references.pmid: 12869693
references.citation: Curr Opin Immunol. 2004 Aug;16(4):443-50
references.pmid: 15245737
references.citation: MMWR Morb Mortal Wkly Rep. 2003 Oct 3;52(39):933-6
references.pmid: 14523370
references.citation: J Am Coll Cardiol. 2004 Jul 7;44(1):201-5
references.pmid: 15234435
references.citation: Appl Microbiol. 1973 Apr;25(4):539-44
references.pmid: 4633476